Agilvax, Inc., a Albuquerque, New Mexico-based biotechnology company that develops targeted cancer immunotherapies and vaccines, completed a Series A1 financing, which complements the Series A round from 2014.
Both Series A and A1 were led by Hunt Holdings with a co-investment by Sun Mountain Capital.
The funds will be used to expand the pre-IND studies for its lead program AX09 in triple negative breast cancer (TNBC). The company is also evaluating the use of AX09 in combination with other cancer therapeutics, as well as strengthening its immunotherapy platform.
Founded in 2011 and led by Federica Pericle, Ph.D., MBA, CEO, Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Its lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells.
The company has offices in El Paso and Houston, Texas.